Omalizumab Therapy for Bullous Pemphigoid: A Case Report. [PDF]
Alsantali A +5 more
europepmc +1 more source
Rapid Clinical Response to Omalizumab Treatment in Pediatric Acute Urticaria Associated with Mycoplasma Infection: A Two-Case Report. [PDF]
Wu ZL, Huang YS, Chiang CT, Yu HR.
europepmc +1 more source
Comparative effectiveness of biologics in lung function improvement among patients with severe asthma: a real-world study. [PDF]
Bourdin A +12 more
europepmc +1 more source
Baseline Monocyte Count Predicts Complete Response to Omalizumab in Chronic Spontaneous Urticaria: A Retrospective Analysis. [PDF]
Turhan İD, Solak B.
europepmc +1 more source
Clinical and molecular aspects of managing chronic spontaneous urticaria: identifying endotypes, phenotypes, and determinants of treatment response and resistance. [PDF]
Su Küçük Ö, Yücel MB.
europepmc +1 more source
A phase 2 randomized controlled trial using biologics to improve multi OIT outcomes (COMBINE): design, rationale, and methods. [PDF]
Long AJ +27 more
europepmc +1 more source
Related searches:
* Omalizumab is a recombinant humanised monoclonal antibody which specifically binds to the C epsilon3 domain of immunoglobulin (Ig) E, the site of high-affinity IgE receptor binding. * Improvements in asthma symptoms and health-related quality-of-life, and a significant reduction in the frequency of asthma exacerbations were seen in allergic asthmatic
S, Easthope, B, Jarvis
openaire +3 more sources

